GDC-2992

• Description :

  GDC-2992 (Compound 28A) is an orally bioavailable androgen receptor (AR) PROTAC degrader. GDC-2992 degrads AR with a DC50 value of 2.7 nM and inhibits proliferation with an IC50 valude of 9.7 nM in VCaPcells. GDC-2992 can be used for prostatic cancer study. (Structure Note: Pink: target protein ligand (HY-130845) ; Blue: E3 ligase ligand (HY-W1003189A) ; Black: linker (HY-169975) ; E3 ligase ligand +linker (HY-169976A) ) [1].

• Product Name Alternative :

  RO7656594

• UNSPSC :

  12352005

• Target :

  Androgen Receptor; PROTACs

• Related Pathways :

  PROTAC; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Purity :

  99.38

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  N#CC1=CC=C(O[C@H]2C(C)(C)[C@H](NC(C3=CC=C(N4CCC(CN5CCN(C6=CC(C=NN([C@@H]7C(NC(CC7)=O)=O)C8=O)=C8C=C6)CC5)CC4)C=C3)=O)C2(C)C)C=C1Cl

• Molecular Formula :

  C45H51ClN8O5

• Molecular Weight :

  819.39

• References & Citations :

  [1]HF Lu, et al. Phthalazinone compound, and preparation method therefor and medical use thereof. WO2021249534A1.|[2]Ciara Metcalfe, et al. Abstract ND02: GDC-2992: A heterobifunctional Androgen Receptor (AR) antagonist and degrader for the treatment of AR wild-type and mutant prostate cancer. Cancer Res (2025) 85 (8_Supplement_2) : ND02.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [2753651-10-2]